U.S. IPO Weekly Recap: Summer IPO Market Marches On With More Small Deals
Six small deals priced this past week, though only three met the criteria for our 2022 IPO stats.
Source: seekingalpha.com
Page 9 - Third Harmonic Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Third Harmonic Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Third Harmonic Bio Today - Breaking & Trending Today
Inflammatory disease biotech Third Harmonic Bio files for a $150 million IPO
Third Harmonic Bio, a Phase 1 biotech developing treatment for allergic and inflammatory diseases, filed on Tuesday with the SEC to raise up to $150 million in an initial public offering. - Renaissance Capital
Source: renaissancecapital.com
Third Harmonic pushes IPO window open with inflammation drug from Novartis
Third Harmonic Bio, which emerged from stealth early this year with a lead drug from Novartis and a $105 million round of funding, has not yet set any financial terms for its planned IPO. But the biotech plans to use the IPO cash for clinical early and mid-stage clinical tests of its small molecule in multiple inflammatory indications.
Source: medcitynews.com
PsiOxus Therapeutics Appoints Howard Davis, Ph.D. as Chief Executive Officer
Dr. Davis brings more than 20 years of industry experience to lead the advancement of the company’s clinical stage pipeline of T-SIGn® immuno-oncology therapeutics for the treatment of solid tumorsNew CEO will establish U.S. operations in the Boston area to accelerate the company’s mission to positively impact the l...
Source: pharmiweb.com
Third Harmonic Bio Appoints Thomas M. Soloway to its Board
CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company developing a potent, highly...
Source: globenewswire.com